Regulatory Status

🇺🇸 United States

Grey Area

Included in the PeptideUnicorn FDA reclassification tracker as under review.

FDA · Updated May 2026

🇬🇧 United Kingdom

Research Use Only

Generally treated as research-only outside licensed channels.

MHRA · Updated May 2026

🇦🇺 Australia

Not Assessed

Not listed in the public tracker dataset; supply claims require case-by-case review.

TGA · Updated May 2026

🏅 WADA

Banned

Growth-hormone secretagogues are prohibited for athletes subject to anti-doping rules.

WADA · Updated May 2026

Overview

Hexarelin is a synthetic growth hormone secretagogue discussed in endocrine, recovery, and body-composition research. PeptideUnicorn currently treats this as a stub profile while the editorial team expands the evidence summary, legal status notes, and citations.

Regulatory Context

Hexarelin is included in the 2026 FDA peptide reclassification tracker as under review. This page is educational only and should not be interpreted as medical, legal, or sourcing advice.

Readers also explore

All peptides →

Growth Hormone

GHRP-2

Growth Hormone Releasing Peptide-2

Growth hormone signaling · Body composition research

Open profile

Growth Hormone

GHRP-6

Growth Hormone Releasing Peptide-6

Growth hormone signaling · Appetite research

Open profile

Growth Hormone

Ipamorelin

Ipamorelin Acetate

growth hormone release · muscle growth · fat loss

Open profile